Letetresgene autoleucel

DRUG2 trials

Sponsors

GlaxoSmithKline, USWM, LLC (dba US WorldMeds)

Conditions

Neoplasms

Phase 1

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

TerminatedNCT03168438

GlaxoSmithKlineNeoplasms

Start: 2017-08-18End: 2020-11-05Updated: 2022-01-11

Phase 2

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

CompletedNCT05993299

USWM, LLC (dba US WorldMeds)Neoplasms

Start: 2019-12-31End: 2026-03-17Updated: 2026-09-02

Related Papers

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma

Blood Advances2022-12-196 citations

Safety and Efficacy of Letetresgene Autoleucel (lete-cel; GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Blood2021-11-05

Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma.

Journal of Clinical Oncology2020-05-203 citations

False positive HIV testing after T-cell receptor therapy

AIDS2020-05-089 citations

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Blood2019-11-133 citations